Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas

19 de outubro de 2017 atualizado por: Steven J. Russell, MD, PhD, Massachusetts General Hospital

The Summer Camp Study 2: Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population Ages 6-11 at the Clara Barton Diabetes Camps

This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs. usual care for young people with type 1 diabetes ages 6-11 years old in a diabetes camp environment.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

19

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

6 anos a 11 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria

  • Age 6-11 years with type 1 diabetes for at least one year
  • Diabetes managed using an insulin infusion pump for ≥ three months
  • Willing to wear two infusion sets and continuous glucose monitoring (CGM) sensor and change sets frequently (at least one new glucagon infusion set daily)
  • Otherwise healthy (mild chronic disease such as asthma will be allowed if well controlled that do not require medications that result in exclusion)

Exclusion Criteria

  • Unable to provide informed consent, informed assent or parental consent
  • Unable to comply with study procedures
  • Current participation in another diabetes-related clinical trial that, in the judgment of the principal investigator, will compromise the results of this study or the safety of the subject
  • End stage renal disease on dialysis (hemodialysis or peritoneal dialysis)
  • Pregnancy (positive urine human chorionic gonadotropin [HCG])
  • History of liver disease that is expected to interfere with the anti-hypoglycemia action of glucagon (e.g. liver failure or cirrhosis). Other liver disease (i.e. active hepatitis, steatosis, active biliary disease, any tumor of the liver, hemochromatosis, glycogen storage disease) may exclude the subject if it causes significant compromise to liver function or may do so in an unpredictable fashion
  • Personal history of cystic fibrosis, pancreatitis, or other pancreatic disease, including pancreatic tumor or insulinoma
  • History of prolonged QT or arrhythmia, congenital heart disease or current known cardiac disease
  • Acute illness (other than non-vomiting viral illness) or exacerbation of chronic illness other than type 1 diabetes (T1D) at the time of the study
  • Seizure disorder, history of any seizure within the last two years, or ongoing treatment with anticonvulsants
  • Untreated or inadequately treated mental illness (indicators would include symptoms such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the last year), or treatment with second generation anti-psychotic medications, which are known to affect glucose regulation.
  • Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to radio-frequency (RF) interference
  • Use of oral (e.g. thiazolidinediones, biguanides, sulfonylureas, glitinides, dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose linked transporter 2 (SGLT-2) inhibitors) anti-diabetic medications
  • History of adverse reaction to glucagon (including allergy) besides nausea and vomiting.
  • Unwilling or unable to completely avoid acetaminophen during the comparator and bionic pancreas arms of the study
  • History of eating disorder such as anorexia, bulimia, or diabulemia or omission of insulin to manipulate weight
  • History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment
  • Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study procedures

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Bionic Pancreas
Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
Dispositivo: Bionic Pancreas
Automated blood glucose control via a closed-loop bionic pancreas device.
Outros nomes:
  • Pâncreas Biônico da Universidade de Boston
Experimental: Usual Care
Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
Outro: Usual Care
As a comparator control, usual diabetes camp care with the participant's own insulin pump.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5
Prazo: Days 2 to 5 of each period
Glucose reading were taken every 5 minutes by the CGM. The CGM glucose results during Days 2 through 5 were averaged.
Days 2 to 5 of each period
Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5
Prazo: Days 2 to 5 of each period
Glucose reading were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than 60 mg/dL [3.3 millimoles/liter (mmol/L)] during Days 2 through 5 was calculated.
Days 2 to 5 of each period

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Mean CGMG Values
Prazo: Day 1 and Days 1-5 in each period
Glucose reading were taken every 5 minutes by the CGM. The glucose results for each time frame were averaged.
Day 1 and Days 1-5 in each period
Percentage of Time With CGMG Concentration by Ranges During Day 1
Prazo: Day 1 of each period
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dL(2.8 mmol/L), < 70 mg/dL (3.9 mmol/L), 70-180 mg/dL (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Day 1 of each period
Percentage of Time With CGMG Concentration by Ranges During Days 1 to 5
Prazo: Days 1 to 5 of each period
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dl (2.8 mmol/L), < 70 mg/dl (3.9 mmol/L), 70-180 mg/dl (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Days 1 to 5 of each period
Percentage of Time With CGMG Concentration by Ranges During Days 2 to 5
Prazo: Days 2 to 5 of each period
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dl (2.8 mmol/L), < 70 mg/dl (3.9 mmol/L), 70-180 mg/dl (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Days 2 to 5 of each period
Percentage of Participants With Mean CGMG Glucose <154 mg/dL
Prazo: Day 1, Days 1-5, and Days 2-5 of each period
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.0%.
Day 1, Days 1-5, and Days 2-5 of each period
Percentage of Participants With Mean CGMG Glucose <169 mg/dL
Prazo: Day 1, Days 1-5, and Days 2-5 of each period
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 169 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.5%.
Day 1, Days 1-5, and Days 2-5 of each period
Percentage of Participants With Mean CGMG Glucose <183 mg/dL
Prazo: Day 1, Days 1-5, and Days 2-5 of each period
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 183 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 8.0%.
Day 1, Days 1-5, and Days 2-5 of each period
Number of CGMG Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)
Prazo: Days 1-5
A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of < 70, < 60, and <50 mg/dL.
Days 1-5
Mean Plasma Glucose Values
Prazo: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. The plasma glucose results on Day 1, Days 1 to 5 and Days 2 to 5 were averaged.
Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Day 1
Prazo: Day 1 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dl (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dl (2.8 mmol/L).
Day 1 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Days 1 to 5
Prazo: Days 1 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dL (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dL (2.8 mmol/L).
Days 1 to 5 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Days 2 to 5
Prazo: Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dl (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dl (2.8 mmol/L).
Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <154 mg/dL
Prazo: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.0%.
Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <169 mg/dL
Prazo: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 169 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.5%.
Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <183 mg/dL
Prazo: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 183 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 8.0%.
Day 1, Days 1 to 5, and Days 2 to 5 of each period
Number of Plasma Glucose Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)
Prazo: Days 1-5
A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of < 70, < 60, and <50 mg/dL.
Days 1-5
Percentage of Days That CGM Data Was Used by Participants as Part of Their Usual Care
Prazo: Day 1, Days 1-5, and Days 2-5 of the Usual Care Period
The percentage of days during the Usual Care period that participants used CGM data as part of their diabetes management.
Day 1, Days 1-5, and Days 2-5 of the Usual Care Period
Number of Carbohydrate Interventions for Hypoglycemia When Plasma Glucose <70 mg/dL
Prazo: Day 1, Days 1-5, and Days 2-5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). Participants were given 15 grams (g) of simple carbohydrates if their plasma glucose concentration dropped below 4.4 mmol/L. These simple carbohydrates were counted as interventions for study outcomes if the plasma glucose concentration was less than 3.9 mmol/L. A second intervention of 15 g of carbohydrate was given if a repeat measurement in 15-20 min was less than 3.9 mmol/L. The total number of carbohydrate interventions are reported.
Day 1, Days 1-5, and Days 2-5 of each period
Grams of Carbohydrate Taken for Hypoglycemia When Plasma Glucose <70 mg/dL
Prazo: Day 1, Days 1-5, and Days 2-5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). Participants were given 15 grams (g) of simple carbohydrates if their plasma glucose concentration dropped below 4.4 mmol/L. These simple carbohydrates were counted as interventions for study outcomes if the plasma glucose concentration was less than 3.9 mmol/L. A second intervention of 15 g of carbohydrate was given if a repeat measurement in 15-20 min was less than 3.9 mmol/L.
Day 1, Days 1-5, and Days 2-5 of each period
Insulin Total Daily Dose
Prazo: 11 days
Insulin total daily dose is reported in units per kilogram per day (U/kg/day).
11 days
Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm
Prazo: Day 1, Days 1-5, and Days 2-5 of each period
Glucagon dose level is reported in micrograms per kilogram of body mass per day (µg/kg/day).
Day 1, Days 1-5, and Days 2-5 of each period
Daily Basal Insulin Dose in the Bionic Pancreas Period
Prazo: Day 1 through Day 5
The bionic pancreas automatically adapted insulin dosing to each individual's needs. When CGM data were not available (because of sensor failure or during the warm-up time after sensor replacement), the bionic pancreas automatically delivered a dose of basal insulin based on the mean basal dosing it had calculated at that time on previous days. Daily basal insulin dose is reported in units per kilogram (kg) per day (U/kg).
Day 1 through Day 5
Daily Bolus Insulin Dose in the Bionic Pancreas Period
Prazo: Day 1 through Day 5
The first time the bionic pancreas was used in each participant, a partial meal-priming bolus based on the participant's body mass (0.05 units/kg) was delivered. After the first use, the size of the meal-priming bolus was adapted by the bionic pancreas to 75% of the 4-hour prandial insulin used for that meal type and size. Daily bolus insulin dose is reported in units per kilogram (kg) per day (U/kg).
Day 1 through Day 5
Carbohydrate Intake
Prazo: Day 1, Days 1-5 and Days 2-5
Carbohydrate intake included meals, snacks and unscheduled carbohydrates administered when a participant's blood glucose was <80 mg/dl (or for symptoms at any glucose level). Carbohydrate intake per day was averaged and is reported in grams (g) per kilogram (kg) per day (g/kg/day).
Day 1, Days 1-5 and Days 2-5
Number of Unscheduled Infusion Set Changes
Prazo: Day 1
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Day 1
Number of Unscheduled Infusion Set Changes
Prazo: Days 1-5
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Days 1-5
Number of Unscheduled Infusion Set Changes
Prazo: Days 2-5
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Days 2-5
Number of Bionic Pancreas Local Infusion Site Reactions
Prazo: Day 1, Days 1-5 and Days 2-5
Local infusion site reactions are defined as pain at the infusion site of the Bionic Pancreas. Itching and redness may have also been present.
Day 1, Days 1-5 and Days 2-5
Mean Nausea Index Score Using a Visual Analogue Scale (VAS)
Prazo: Day 1, Days 1-5, and Days 2-5 in each period
Participants rated their nausea using a 0 to 10 centimeter (cm) VAS where 0=least severe nausea to 10=most severe nausea. The average nausea index scores from Day 1 to Day 5 were calculated
Day 1, Days 1-5, and Days 2-5 in each period
Number of Severe Hypoglycemic Events
Prazo: Day 1, Days 1-5 and Days 2-5
A severe hypoglycemic event is an event where the participant is unable to self-treat and requires the assistance of another person.
Day 1, Days 1-5 and Days 2-5
Percentage of Time Participants Were Not Under Bionic Pancreas Control During the Bionic Pancreas Period
Prazo: 5 days
Percentage of time that the Bionic pancreas was not functioning properly due to loss of wireless connectivity.
5 days
Percentage of Time Without CGM Monitoring Data
Prazo: 5 days
Percentage of time without CGM monitoring data is the time when the participant's CGM device lost its CGM signal.
5 days
Change From Baseline in Body Weight
Prazo: 5 days
The change in body weight collected at Day 5 of each period relative to Baseline. A negative change from Baseline indicates a reduction in body weight and a positive change from Baseline indicates an increase in body weight.
5 days
Reliability Index
Prazo: Day 1, Days 1-5, and Days 2-5 in each period
Reliability index was calculated as the percentage of time values were actually recorded by CGM.
Day 1, Days 1-5, and Days 2-5 in each period
List of Technical Faults Associated With the Bionic Pancreas Including Cause and Resolution
Prazo: 5 days
5 days
Number of Unscheduled CGM Sensor Changes
Prazo: 5 days
The number of time a CGM sensor was replaced due to falling out or failing to report a glucose value.
5 days
Percentage of Participants Using a Glucagon-Like Peptide-1 (GLP-1) Agonist During the Usual Care Period
Prazo: 5 days
The percentage of participants who used a GLP-1 agonist to manage their diabetes during the Usual Care period.
5 days
Percentage of Participants Using Pramlintide During the Usual Care Period
Prazo: 5 days
The percentage of participants who used pramlintide to manage their diabetes during the Usual Care period.
5 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Massachusetts General Hospital

Colaboradores

Boston University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de junho de 2014

Conclusão Primária (Real)

1 de agosto de 2014

Conclusão do estudo (Real)

1 de agosto de 2014

Datas de inscrição no estudo

Enviado pela primeira vez

2 de abril de 2014

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de abril de 2014

Primeira postagem (Estimativa)

7 de abril de 2014

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de outubro de 2017

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de outubro de 2017

Última verificação

1 de outubro de 2017

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 2014P000630

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever